AstraZeneca (AZ) has reached a settlement with the European Commission that confirms the delivery of Vaxzevria vaccine doses to the continent and resolves the ongoing legal proceedings that the bloc had started against the company. The agreement will see AZ deliver 60 million vaccine doses by the end of Q3 2021, 75 million by the end of Q4 2021 and 65 million by the end of Q1 2022. The company will provide regular delivery schedules to EU member states and will issue capped rebates if any deliveries are delayed. The deal has ended the Commission’s legal proceedings against AZ, which were due to go to court at the end of September.
The US Government plans to invest $3bn in its Covid-19 vaccine supply chain as part of its efforts to boost the country’s manufacturing capacity for vital vaccine components. Companies manufacturing vaccine inputs will be able to access these funds to add production lines and facilities, as well as to bolster fill-finish capacity. The investment is expected to create thousands of jobs in the US and expand the country’s capacity to respond to infectious disease outbreaks in the future.
MGC Pharmaceuticals has received approval to import its phytomedicine CimetrA into India. This will enable the final product assessment to conclude the company’s application for Emergency Use Authorisation to treat Covid-19 patients. Medopharm will import and market the therapy in the country. CimetrA is currently being assessed in a Phase III trial in Israel for the treatment of Covid-19.